ResearcherUniversity of UtahNo recent work listed
John F. Timms
Matched on ORCID iD 0000-0002-4507-835X; OpenAlex author ID A5020418534. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Labs led
- 1
- Collaborators
- 18
2011: 1 paper · 2012: none · 2013: none · 2014: none · 2015: 2 papers · 2016: 1 paper · 2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper
Papers 6
- Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes. Co-author DOI 10.1016/j.ebiom.2021.103802↗
- Evidence of Altered Glycosylation of Serum Proteins Prior to Pancreatic Cancer Diagnosis. Last author DOI 10.3390/ijms18122670↗
- Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. Co-author DOI 10.1158/1078-0432.ccr-15-0879↗
- Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer. Co-author DOI 10.1016/j.jprot.2014.10.001↗
- Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early disease detection. Last author DOI 10.1158/1078-0432.ccr-14-0365↗
- AGR2 is a novel surface antigen that promotes the dissemination of pancreatic cancer cells through regulation of cathepsins B and D. Co-author DOI 10.1158/0008-5472.can-11-1367↗
Closest collaborators
The 18 strongest of 18 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Stephen P. Pereira · 5 shared papers, 2015–2022 · strength 0.34
- Paper Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic ca… DOI 10.1016/j.ebiom.2021.103802↗
- Paper Evidence of Altered Glycosylation of Serum Proteins Prior to Pancreatic Cancer Diagnosis. DOI 10.3390/ijms18122670↗
- Paper Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Asso… DOI 10.1158/1078-0432.ccr-15-0879↗
- Claire Jenkinson · 4 shared papers, 2015–2022 · strength 0.26
- Paper Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic ca… DOI 10.1016/j.ebiom.2021.103802↗
- Paper Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Asso… DOI 10.1158/1078-0432.ccr-15-0879↗
- Paper Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cance… DOI 10.1016/j.jprot.2014.10.001↗
- Eithne Costello · 4 shared papers, 2015–2022 · strength 0.26
- Paper Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic ca… DOI 10.1016/j.ebiom.2021.103802↗
- Paper Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Asso… DOI 10.1158/1078-0432.ccr-15-0879↗
- Paper Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cance… DOI 10.1016/j.jprot.2014.10.001↗
- William Greenhalf · 3 shared papers, 2015–2022 · strength 0.22
- Paper Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic ca… DOI 10.1016/j.ebiom.2021.103802↗
- Paper Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Asso… DOI 10.1158/1078-0432.ccr-15-0879↗
- Paper Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cance… DOI 10.1016/j.jprot.2014.10.001↗
- Lucy S. Oldfield · 2 shared papers, 2016–2022 · strength 0.18
- Paper Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic ca… DOI 10.1016/j.ebiom.2021.103802↗
- Paper Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Asso… DOI 10.1158/1078-0432.ccr-15-0879↗
- Paula Ghaneh · 1 shared paper, 2022 · strength 0.14
- Christopher Michael Halloran · 1 shared paper, 2022 · strength 0.14
- John P. Neoptolemos · 2 shared papers, 2015–2016 · strength 0.09
- Paper Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Asso… DOI 10.1158/1078-0432.ccr-15-0879↗
- Paper Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cance… DOI 10.1016/j.jprot.2014.10.001↗
- Darragh Patrick O'Brien · 2 shared papers, 2015–2016 · strength 0.08
- Paper Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Asso… DOI 10.1158/1078-0432.ccr-15-0879↗
- Paper Serum CA19-9 is significantly upregulated up to 2 years before diagnosis with pancreatic cancer: implications for early… DOI 10.1158/1078-0432.ccr-14-0365↗
- Shibu Krishnan · 1 shared paper, 2017 · strength 0.07
- David Arthur Tuveson · 1 shared paper, 2016 · strength 0.04
- Alexey A. Zaikin · 1 shared paper, 2015 · strength 0.04
- Ross C. Smith · 1 shared paper, 2015 · strength 0.04
- Oleg B. Blyuss · 1 shared paper, 2015 · strength 0.04
- Laurent Dumartin · 1 shared paper, 2011 · strength 0.02
- Teresa A. Brentnall · 1 shared paper, 2011 · strength 0.02
- Christine A. Iacobuzio–Donahue · 1 shared paper, 2011 · strength 0.02
- Tatjana Crnogorac‐Jurcevic · 1 shared paper, 2011 · strength 0.02
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.